Talaris Therapeutics (TALS) Stock Price, News & Analysis

Company Overview

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

Key Stats

• Today's Range: $16.11 to $16.52
• 50-Day Range: $12.36 to $28.36
• 52-Week Range: $0.89 to $27.95
• Volume: 59,085 shs
• Average Volume: 386,531 shs
• Market Capitalization: $702.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TALS Stock Analysis - Frequently Asked Questions

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03.

When did Talaris Therapeutics IPO?

Talaris Therapeutics (TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.

What other stocks do shareholders of Talaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Talaris Therapeutics investors own include Graphite Bio (GRPH), Vaccitech (VACC), Achilles Therapeutics (ACHL), Allogene Therapeutics (ALLO), Cytec Industries (CYT), Immunocore (IMCR) and Century Therapeutics (IPSC).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 7/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TALS
• CIK: 1827506
• Web: talaristx.com
• Phone: 502-398-9250
• Fax: N/A
• Employees: 84
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.89 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -39.93%
• Return on Assets: -37.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.41
• Quick Ratio: 15.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 3.79

Miscellaneous

• Outstanding Shares: 42,764,000
• Free Float: 35,708,000
• Market Cap: $702.18 million
• Optionable: Not Optionable
• Beta: 2.18